Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 5
1999 6
2000 12
2001 25
2002 44
2003 78
2004 113
2005 112
2006 122
2007 147
2008 178
2009 153
2010 154
2011 156
2012 159
2013 145
2014 177
2015 139
2016 121
2017 99
2018 99
2019 80
2020 773
2021 529
2022 202
2023 114
2024 79
2025 59
2026 25

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,713 results

Results by year

Filters applied: . Clear all
Page 1
Lopinavir/Ritonavir for COVID-19: a Systematic Review and Meta-Analysis.
Amani B, Khanijahani A, Amani B, Hashemi P. Amani B, et al. J Pharm Pharm Sci. 2021;24:246-257. doi: 10.18433/jpps31668. J Pharm Pharm Sci. 2021. PMID: 34048671 Free article.
There was no significant difference between lopinavir/ritonavir and chloroquine as well as lopinavir/ritonavir and hydroxychloroquine regarding the efficacy outcomes (P>0.05). However, lopinavir/ritonavir showed better efficacy than ar …
There was no significant difference between lopinavir/ritonavir and chloroquine as well as lopinavir/ritonavir a …
Lopinavir-Ritonavir in SARS-CoV-2 Infection and Drug-Drug Interactions with Cardioactive Medications.
Agarwal S, Agarwal SK. Agarwal S, et al. Cardiovasc Drugs Ther. 2021 Jun;35(3):427-440. doi: 10.1007/s10557-020-07070-1. Epub 2020 Sep 12. Cardiovasc Drugs Ther. 2021. PMID: 32918656 Free PMC article. Review.
Lopinavir-ritonavir combination is being used for the treatment of SARS-CoV-2 infection. A low dose of ritonavir is added to other protease inhibitors to take advantage of potent inhibition of cytochrome (CYP) P450 3A4, thereby significantly increasing the pl …
Lopinavir-ritonavir combination is being used for the treatment of SARS-CoV-2 infection. A low dose of ritonavir is add …
Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review.
Vargas M, Servillo G, Einav S. Vargas M, et al. Eur Rev Med Pharmacol Sci. 2020 Aug;24(16):8592-8605. doi: 10.26355/eurrev_202008_22659. Eur Rev Med Pharmacol Sci. 2020. PMID: 32894567 Free article.
RESULTS: Five in-vitro studies evaluated the effect of lopinavir/ritonavir in SARS. Three additional in-vitro studies reported the EC50 of the antiviral activity of lopinavir/ritonavir in MERS. ...Three case reports and one retrospective study describe …
RESULTS: Five in-vitro studies evaluated the effect of lopinavir/ritonavir in SARS. Three additional in-vitro studies reported …
Monotherapy with lopinavir/ritonavir.
Schechter M, Nunes EP. Schechter M, et al. Expert Opin Investig Drugs. 2007 May;16(5):735-41. doi: 10.1517/13543784.16.5.735. Expert Opin Investig Drugs. 2007. PMID: 17461744 Review.
Given the encouraging results of available studies on lopinavir/ritonavir monotherapy in patients with no prior failure with protease inhibitors, it may be warranted to conduct trials to investigate the cost-effectiveness of lopinavir/ritonavir monothe …
Given the encouraging results of available studies on lopinavir/ritonavir monotherapy in patients with no prior failure with p …
Lopinavir/Ritonavir: A Review of Analytical Methodologies for the Drug Substances, Pharmaceutical Formulations and Biological Matrices.
Velozo CT, Cabral LM, Pinto EC, de Sousa VP. Velozo CT, et al. Crit Rev Anal Chem. 2022;52(8):1846-1862. doi: 10.1080/10408347.2021.1920364. Epub 2021 May 23. Crit Rev Anal Chem. 2022. PMID: 34024199 Review.
Lopinavir/ritonavir is a potent coformulation of protease inhibitors used against HIV infection. Lopinavir is the main responsible for viral load suppression, whereas ritonavir is a pharmacokinetic enhancer. ...
Lopinavir/ritonavir is a potent coformulation of protease inhibitors used against HIV infection. Lopinavir is the main …
Efficacy and safety of lopinavir/ritonavir in the treatment of COVID-19: A systematic review.
Joseph BA, Dibas M, Evanson KW, Paranjape G, Vegivinti CTR, Selvan PT, Saravu K, Gupta N, Pulakurthi YS, Keesari PR, Varsha S, Chittajallu S, Dmytriw AA, Reierson NL, Mikoff N, Kamrowski S, Schmidt M, Davis AR, Pederson JM, Mishra HK, Touchette JC, Kallmes K. Joseph BA, et al. Expert Rev Anti Infect Ther. 2021 Jun;19(6):679-687. doi: 10.1080/14787210.2021.1848545. Epub 2020 Dec 21. Expert Rev Anti Infect Ther. 2021. PMID: 33187459
Objectives: To systematically review the clinical literature reporting the use of Lopinavir/ritonavir (LPV/r) for the treatment of patients with Cornonavirus disease 19 (COVID-19) to assess the efficacy of LPV/r for the treatment of COVID-19.Methods: The authors sys …
Objectives: To systematically review the clinical literature reporting the use of Lopinavir/ritonavir (LPV/r) for the treatmen …
BET 1: Lopinavir-ritonavir and COVID-19.
Dolan D, Ingham J, Baombe J. Dolan D, et al. Emerg Med J. 2020 Jul;37(7):450-451. doi: 10.1136/emermed-2020-210221.2. Emerg Med J. 2020. PMID: 32616658 Review. No abstract available.
Lopinavir/ritonavir.
Porche DJ. Porche DJ. J Assoc Nurses AIDS Care. 2001 Mar-Apr;12(2):101-4. doi: 10.1016/S1055-3290(06)60137-4. J Assoc Nurses AIDS Care. 2001. PMID: 11296724 Review.
Safety and efficacy of lopinavir/ritonavir during pregnancy: a systematic review.
Pasley MV, Martinez M, Hermes A, d'Amico R, Nilius A. Pasley MV, et al. AIDS Rev. 2013 Jan-Mar;15(1):38-48. AIDS Rev. 2013. PMID: 23449228
Studies were selected that included HIV-infected pregnant mothers treated with a lopinavir/ritonavir-based regimen and described relevant maternal and infant outcomes. Ten articles or presentations describing nine studies were identified, comprising 2,675 lopinav …
Studies were selected that included HIV-infected pregnant mothers treated with a lopinavir/ritonavir-based regimen and describ …
Efficacy and safety of lopinavir-ritonavir in COVID-19: A systematic review of randomized controlled trials.
Patel TK, Patel PB, Barvaliya M, Saurabh MK, Bhalla HL, Khosla PP. Patel TK, et al. J Infect Public Health. 2021 Jun;14(6):740-748. doi: 10.1016/j.jiph.2021.03.015. Epub 2021 Apr 20. J Infect Public Health. 2021. PMID: 34020215 Free PMC article.
BACKGROUND: Lopinavir-ritonavir is a repurposed drug for coronavirus disease-2019 (COVID-19). In this study, a pooled effect of lopinavir-ritonavir on mortality, virological cure, radiological improvement and safety profile in COVID-19 patients has bee …
BACKGROUND: Lopinavir-ritonavir is a repurposed drug for coronavirus disease-2019 (COVID-19). In this study, a pooled effect o …
3,713 results